Christina Kay
2023
In 2023, Christina Kay earned a total compensation of $301.3K as Co, Chief Executive Officer at Integrated Biopharma, a 9% increase compared to previous year.
Compensation breakdown
| Bonus | $6,400 |
|---|---|
| Option Awards | $48,225 |
| Salary | $237,273 |
| Other | $9,417 |
| Total | $301,315 |
Kay received $237.3K in salary, accounting for 79% of the total pay in 2023.
Kay also received $6.4K in bonus, $48.2K in option awards and $9.4K in other compensation.
Rankings
In 2023, Christina Kay's compensation ranked 2,514th out of 2,983 executives tracked by ExecPay. In other words, Kay earned more than 15.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,514 out of 2,983 | 16th |
Division Manufacturing | 1,403 out of 1,637 | 14th |
Major group Chemicals And Allied Products | 807 out of 906 | 11th |
Industry group Drugs | 787 out of 869 | 9th |
Industry Pharmaceutical Preparations | 562 out of 627 | 10th |
Source: SEC filing on October 27, 2023.
Kay's colleagues
We found three more compensation records of executives who worked with Christina Kay at Integrated Biopharma in 2023.
News
Integrated Biopharma CFO Dina Masi's 2024 pay rises 8% to $357K
October 28, 2024
Integrated Biopharma CFO Dina Masi's 2023 pay rises 10% to $330K
October 27, 2023
Integrated Biopharma CFO Dina Masi's 2022 pay rises 12% to $300K
October 27, 2022
Integrated Biopharma CFO Dina Masi's 2021 pay rises 6% to $268K
October 27, 2021
Integrated Biopharma CFO Dina Masi's 2019 pay rises 4% to $251K
October 28, 2019